Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 15-26 , February 1998

Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?

  • M. Colleoni

      Affiliations

    • Corresponding Author InformationCorrespondence: M. Colleoni, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
    • Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    • ,
  • A. Coates

      Affiliations

    • Australian New Zealand Breast Cancer Trials Group, Departments of Medicine, University of Sydney and Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia
    • ,
  • O. Pagani

      Affiliations

    • Servizio Oncologico Cantonale, Ospedale Beata Vergine, Mendrisio, Switzerland
    • ,
  • A. Goldhirsch

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    • Servizio Oncologico Cantonale, Ospedale Beata Vergine, Mendrisio, Switzerland

References 

  1. Valagussa P, Bonadonna G, Veronesi U, et al.  Patterns of relapse and survival following radical mastectomy. In: Analysis of 761 consecutive patients. Cancer. 41:1978;p. 1170–1178
  2. Martin DS, Fughan RA. A role of chemotherapy as an adjunct to surgery. Cancer Res. 1957;17:1098–1101
  3. Fisher R, Ravdin G, Ausman RK, et al.  Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168:337–356
  4. Martin DS. Clinical implications of the interrelationship of tumor size and chemotherapeutic response. Ann Surgery. 1960;151:97–100
  5. Fisher B, Redmond C, Brown A. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6
  6. Bonadonna G, Brusamolino E, Valagussa P, et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410
  7. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. In: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;p. 1–15 Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. In: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;p. 71–85
  8. Baum M, Brinhley DM, Dossett JA, et al.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at eight years by Nolvadex Adjuvant Trial Organization. Br J Cancer. 1988;57:608–611
  9. Fisher B, Redmond C, Brown A, et al.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer. In: Five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 4:1986;p. 459–471
  10. Osborne CK. Effects of estrogens and antiestrogens on cell proliferation. In: Implications for treatment of breast cancer.  Osborne CK editors. Endocrine Treatment in Breast and Prostate Cancer. Boston: Kluwer; 1988;p. 11–129
  11. Cavalli F, Pedrazzini A, Martz G. Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Cancer Clin Oncol. 1983;19:1615–1624
  12. ANZ Breast Cancer Trials Group. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol. 1986;4:186–193
  13. Rubagotti A, Amoroso D. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. In: Boccardo , et al. editor. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) Trial. Eur J Cancer. 28:1992;p. 673–680
  14. Fisher B, Redmond C, Legault-Poisson S, et al.  Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005–1018
  15. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV. Recent Results Cancer Res. 1990;115:153–162
  16. Rivkin S, Green S, Metch B, et al.  Adjuvant chemotherapy (CMFVP) vs oophorectomy followed by chemotherapy (OCMFVP) for premenopausal women with Er positive operable breast cancer with positive nodes: A SWOG study. J Clin Oncol. 1996;14:46–51
  17. Goldhirsch A, Wood WC, Senn HJ, et al.  In: Meeting Highlights: International Consensus Panel on the treatment of primary breast cancer. J Nat Cancer Institute. 87:1995;p. 14–20
  18. The International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breasts cancer patients. J Clin Oncol. 1997;15:1385–1394
  19. Pritchard KI, Zee B, Paul N, et al.  Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy added to tamoxigen as adjuvant chemotherapy in postmenopausal women with node positive and estrogen receptor positive breast cancer: a report from the NCIC. J Clin Oncol. 1997;15:2302–2311
  20. Fisher B, Dignam J, Wolmark N, et al.  Tamoxifen and chemotherapy in lymph node negative estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673–1682
  21. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380–387
  22. Albain K, Green S, Osborne K, Cobau C, et al. , for SWOG, ECOG, CALGB, NCCTG, and NCI-Canada   Tamoxifen (T) versus cyclophosphamide, Adriamycin® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). In: Proc Am Soc Clin Oncol. 16:1997;p. 128
  23. Rivkin SE, Green S, Metch B, et al.  Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients. A Southwest Oncology Group Study J Clin Oncol. 1994;12:2078–2085
  24. Engelsman E, Klijn JC, Rubens RD, Wildiers J, et al.  “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. In: An EORTIC Breast Cancer Co-operative Group phase III trial (10808). Eur J Cancer. 27:1991;p. 966–970
  25. Gerard JP, Hery M, Gedouin D, et al.  Postmenopausal patients with node-positive resectable breast cancer: tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control. In: Preliminary results of a 4-arm randomized trial. Drugs. 45:1993;p. 60–67
  26. Pearson OH, Hubay CA, Gordon NH, et al.  Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Cancer. 1989;64:1819–1823
  27. Hupperets PSGJ, Wilòs J, Volovis L, et al.  Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and fluorouracil (CAF) with or without medroxyprogesterone acetate for node positive breast cancer patients. Ann Oncol. 1993;4:301–305
  28. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone P. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. In: An ECOG trial. Cancer. 65:1990;p. 200–206
  29. Taylor SG, Knuiman MW, Sleeper LA, et al.  Six-year results of the Eastern Cooperative Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 1989;7:879–889
  30. Schumacher M, Bastert G, Bojar H, et al.  Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol. 1994;12:2086–2093
  31. Kaufmann M, Jonat W, Abel U, et al.  Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol. 1993;11:454–460
  32. Bianco AR, De Placido S, Gallo C, et al.  Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) Study. Lancet. 1988;2:1095–1099
  33. Carbone P, Economou SG, et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. In: Fisher  editors. A report of early findings. N Engl J Med. 292:1975;p. 117–122
  34. Dombernowsky P, Brincker H, Hansen M, et al.  Adjuvant chemotherapy of premenopausal and postmenopausal risk breast cancer patients. Acta Oncol. 1988;27:291–296
  35. Crowe JP, Gordon NH, Shenk RR, Soegiarso RW, Hubay CA. Short term tamoxifen plus chemotherapy: superior results in node-positive breast cancer. Surgery. 1990;10:619–627
  36. Ingle JN, Everson LK, Wieand HS, Martin K, et al.  Randomized trial of observation versus adjuvant therapy with CMGp with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1988;6:1388–1396
  37. Rutqvist LE, Cedermark B, Gla U, et al.  Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer. 1990;66:89–96
  38. Hubay CA, Pearson OH, Manni A, Gordon NH, McGuire WL. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6 year result. J Steroid Biochem. 1985;23:1147–1150
  39. Mauriac L, Durand M, Chauvergne J, Bonichon F, Avril A. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs CMF + tamoxifen in a single centre. Breast Cancer Res Treat. 1988;11:179–186
  40. Blomqvist C, Tiusanen K, Elomaa I, Rissanen P, et al.  The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide, doxorubicin ftorafur and tamoxifen in stage II breast cancer. In: Long term follow up results of a randomized trial. Br J Cancer. 66:1992;p. 1171–1176
  41. Ingle JN, Everson L, Wieand S, et al.  Randomized trial to evaluate the addition of tamoxifen to CMFp adjuvant therapy in premenopausal women with node positive breast cancer. Cancer. 1989;63:1257–1264
  42. Pannuti F, Martoni A, Cilenti G, et al.  Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer. 1988;24:423–429
  43. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res. 1985;45:4454–4459
  44. Fisher B, Sherman B, Rockette H, et al.  L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of DFS with depression of ovarian function. Cancer. 1979;44:847–857
  45. Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. NCI Monogr. 1986;1:55–70
  46. Rossi A, Bonadonna G, Tancini G, et al.  Trials of adjuvant chemotherapy in breast cancer. In: The experience of the Istituto Nazionale Tumori of Milan.  Mouridsen HT,  Palshof T editor. Breast Cancer—Experimental and Clinical Aspects. Oxford: Pergamon; 1980;p. 149–156
  47. Greensberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res. 1987;47:70–76
  48. Berman E, Adams M, Duigou-Ostendorf R, et al.  Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 1991;77:818–822
  49. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol. 1988;22:147–152
  50. Smith G, Henderson IC. New treatments for breast cancer. Sem Oncol. 1996;23:506–508
  51. Goldhirsch A, Gelber RD, Castiglione M, et al.  Present and future project of the International Breast Cancer Study Group. Cancer. 1994;74:1139–1149
  52. Muss HB, Thor AD, Berry D, et al.  C-erbB2 expression and response to adjuvant therapy in women with node positive early breast cancer. New Engl J Med. 1994;330:1260–1266
  53. Wright C, Nicholson S, Angus B, et al.  Relationship between c-erb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118–121
  54. Lowe S, Ruley H, Jacks T, et al.  P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967
  55. Hietanem P, Blomqvist C, Wasenius V-M, et al.  Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer?. Br J Cancer. 1995;71:1029–1032
  56. Makris A, Powles TS, Browsett C, et al.  Prediction of response to neoadjuvant chemoendocrine therapy in operable breast. Clinical Cancer Res. 1997;3:593–600

PII: S0305-7372(98)90068-8

Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 15-26 , February 1998

Article Tools